NCT04030598View on ClinicalTrials.gov

A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 7, 2020

Primary Completion Date

January 4, 2021

Study Completion Date

March 1, 2021

Conditions
Hereditary Angioedema
Interventions
DRUG

Donidalorsen

Donidalorsen administered SC

DRUG

Placebo

Placebo matching solution administered SC

Trial Locations (8)

17033

Penn State Hershey Medical Center, Hershey

45231

Bernstein Clinical Research Center, LLC, Cincinnati

55446

Midwest Immunology Clinical, Plymouth

75231

AARA Research Center, Dallas

85251

Medical Research of Arizona, Scottsdale

90404

AIRE Medical of Los Angeles, Santa Monica

92122

University of California San Diego (UCSD), San Diego

1105 AZ

Amsterdam UMC, loc. AMC, Amsterdam

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY